SCHEMBL3759530

SCHEMBL3759530

CCOC(=O)c1cncc(-c2c(N3CCOCC3)sc3c2CC(C)(C)CC3=O)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 3/20 0.43
PRKDC P78527 1/20 0.41
POLB P06746 1/20 0.40
SIRT2 Q8IXJ6 1/20 0.39
SIRT1 Q96EB6 1/20 0.39
RXFP1 Q9HBX9 1/20 0.38
PIK3CD O00329 2/20 0.38
PIK3CB P42338 2/20 0.38
PIK3CG P48736 2/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
PIK3R2 O00459 1/20 0.37
BRD4 O60885 1/20 0.37
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
EGFR P00533 1/20 0.36
GAA P10253 2/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
LMNA P02545 2/20 0.36
MAPT P10636 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3757774 0.88 PIK3CA (0.41) PIK3CAPRKDCPOLBPIK3CDPIK3CB
SCHEMBL3760325 0.88 PRKDC (0.49) PIK3CAPRKDCPOLBSIRT2SIRT1
SCHEMBL3756709 0.84 PIK3CA (0.47) PIK3CAPRKDCPOLBSIRT2SIRT1
SCHEMBL3765059 0.82 PIK3CA (0.43) PIK3CAPRKDCPIK3CDPIK3CBPIK3CG
SCHEMBL3754664 0.80 GABRA1 (0.42) PIK3CAPRKDCPIK3CDPIK3CBPIK3CG
SCHEMBL3760161 0.79 GABRA1 (0.48) PIK3CAPRKDCPIK3CDPIK3CBPIK3CG
SCHEMBL3755041 0.78 GABRA1 (0.53) PIK3CAPRKDCPIK3CDPIK3CBPIK3CG
SCHEMBL3763668 0.77 PIK3CA (0.42) PIK3CAPRKDCPIK3CDPIK3CBPIK3CG
SCHEMBL3754752 0.77 PRKDC (0.45) PIK3CAPRKDCPOLBPIK3CDPIK3CB
SCHEMBL3760529 0.77 PRKDC (0.47) PIK3CAPRKDCPOLBPIK3CDPIK3CB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2029570-B1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2014-10-15 EP disclosed
US-8324204-B2 Fused thiophene derivatives as kinase inhibitors UCB PHARMA SA (BE) 2012-12-04 US disclosed
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-12-02 US disclosed
EP-2029570-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB Pharma S.A. (BE) 2009-03-04 EP disclosed
WO-2007141504-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2007-12-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors PIKFYVE, PI4KA, PIK3CA PIK3CA 3/4885PRKDC 112/4885POLB 2137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.